MedTrace Logo

Early Detection of Cardiac Damage With CMR in Women With Breast Cancer

NCT04046315 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2020-03-16

No results posted yet for this study

Summary

With this study the investigators will assess early cardiac damage by means of Global Longitudinal Strain (GLS) in newly diagnosed breast cancer (BC) patients treated with anthracycline-based chemotherapy, and to investigate whether myocardial damage as measured with T1 / T2 Cardiovascular Magnetic Resonance (CMR) mapping and plasma hs-Troponin T is related to changes in GLS.

Conditions

Interventions

DIAGNOSTIC_TEST

CMR

GLS measurement with CMR

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Saloua El Messaoudi, PhD · Radboud University Medical Center

  • Angela Maas, PhD · Radboud University Medical Center

  • Robin Nijveldt, PhD · Radboud University Medical Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04046315 on ClinicalTrials.gov